Accelerated iTBS for Post Partum Depression

Study 1: This is an open-label study designed to investigate the feasibility and tolerability of a novel TMS treatment protocol to treat depression in women with post-partum depression. It is known that TMS can effectively treat depression. The FDA approved protocol lasts 6 weeks and is not feasible for many women with post-partum depression. The investigators are investigating a 6 day treatment for depression which may be more acceptable for this population. The investigators further aim to characterize the ant-depressant effect of this protocol in order to design a larger trial.

Study 2: In part 2 of this study, the treatment schedule is 12 sessions over 5 days that can be completed with 8. All other procedures, inclusion/exclusion criteria, and number of total pulses delivered is the same as study 1.

Inclusion criteria

• Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
• Participants must be over the age of 18.
• Participants must meet criteria for post-partum depression: a) onset of symptoms in the first year postpartum
• Participants must have a HRSD17 greater than or equal to 14 at baseline.

Exclusion criteria

• Participants must not be pregnant.
• Participants must not meet moderate or severe use disorder of any substance with the exception of Tobacco Use Disorder.
• Participants must not have current psychotic symptoms.
• Participants must not have a history of dementia or other cognitive impairment.
• Participants must not have active suicidal ideation requiring hospitalization or a suicide attempt within the past 3 months.
• Participants must not have any contraindications to receiving rTMS (e.g. metal implanted above the neck, history of seizure, any known brain lesion).
• Participants must not have any unstable general medical conditions.
• Participants must not have had eclampsia during pregnancy.